GlassScriptPhysician profile
Hernando Zegarra
NPI 1710971098
$478.03
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.41 · 2020: $217 · 2021: $164.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $172.36 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $72.62 | 2019-2021 | |
| Alimera Sciences, INC. | $69.70 | 2020-2021 | |
| Genentech USA, INC. | $55.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.95 | 2019-2021 | |
| Eyepoint US, INC. | $29.06 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.30 | 2021 | |
| Mallinckrodt Hospital Products INC. | $11.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernando Zegarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.